Work

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-166670

Authors: John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera

Institutions: Ronald Reagan UCLA Medical Center, Hadassah Medical Center, Jewish General Hospital, Sheba Medical Center, University Hospital Cologne, University of California, San Francisco, The University of Melbourne, St Vincent's Hospital Melbourne, Monash Health, Monash University, Princess Alexandra Hospital, Rambam Health Care Campus, University Hospital Leipzig, University of Bologna, Merck & Co., Inc., Rahway, NJ, USA (United States), City Of Hope National Medical Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310160993

FWCI: 1.354

Cites:

Cited by: 9

Related to: 10